|
Match
|
Document |
Document Title |
|
|
5422260 |
Human factor VIII:c muteins
This invention relates to recombinant Factor VIII:c variants, methods to produce the variants and pharmaceutical compositions containing same.
|
|
|
5416021 |
Fibronectin binding protein-encoding DNA
The present invention relates to new recombinant DNA-molecules comprising nucleotide sequences of S. dysgalactiae encoding for at least one protein or polypeptide having fibronectin binding property.
|
|
|
5405942 |
Prepro insulin-like growth factors I and II
Polynucleotide sequences which encode for human prepro insulin-like growth factors are provided. Such sequences are obtained from the human genome, typically by screening a cDNA library obtained...
|
|
|
5405946 |
Recombinant protein S variants deficient in C4BP binding activity, compositions and therapeutic methods
The present invention describes a variant protein S protein that is substantially homologous in amino acid residue sequence to wild-type mature human protein S, which has in vitro anticoagulant...
|
|
|
5384250 |
Expression and purification of cloned alpha-fetoprotein
In general, the invention features a method for producing human alpha-fetoprotein in prokaryctic cells. The method includes: providing a transformed prokaryotic cell including a recombinant DNA...
|
|
|
5384263 |
Method to produce immunodiagnostic reagents
Screening methods to obtain suitable antibodies for use in immunoassays for analytes not ordinarily susceptible to detection by this means involves in vitro, screening of panels of cells secreting...
|
|
|
5380712 |
Truncated human serum albumin polypeptides as plasma expanding agents
Polypeptides corresponding to mature human serum albumin residues 1 to n, where n is between 369 and 419 inclusive, are useful as substitutes for albumin in the treatment of burns and shock in...
|
|
|
5378612 |
Culture medium for production of recombinant protein
A culture medium without or with a low level of protein for culturing a transformed animal cell capable of continuously producing a protein prepared by using a genetic engineering technique, which...
|
|
|
5369020 |
Method for suppressing coloring of human serum albumin
A method for suppressing coloring of human serum albumin expressed by genetic engineering, which comprises culture and/or purification in the presence of an amine compound selected from the group...
|
|
|
5356798 |
Recombinant protein production in serum-free medium
In a method for effecting an increased expression in serum-free medium of recombinant proteins in a host cell being able to express said protein said host is cultured in a serum-free medium...
|
|
|
5340727 |
GPIbα fragments and recombinant DNA expression vectors
Recombinant DNA expression vectors encoding a peptide which inhibits binding of von Willebrand factor to platelet membrane glycoprotein Ib, said vector including a nucleotide sequence encoding the...
|
|
|
5334512 |
Fatty acid supplemented medium for recombinant production of human serum albumin by yeast
A method for producing human serum albumin which comprises cultivating a human serum albumin-producing host prepared by genetic engineering, in a medium containing a fatty acid having 10 to 26...
|
|
|
5330901 |
Expression of human serum albumin in Pichia pastoris
A process for the production of HSA in Pichia pastoris cells comprising cultivating Pichia pastoris cells capable of expressing HSA at a pH of about 5.7 to about 6.4 contemporaneously with the...
|
|
|
5321127 |
Antiplatelet and antithrombotic activity of platelet glycoprotein Ib receptor fragments
A platelet glycoprotein Ib receptor fragment, having antiplatelet and antithrombotic activity, useful for blocking platelet adhesion. The invention may be used in the treatment of patients who are...
|
|
|
5316934 |
Effective thrombosis mediated by human prourokinase-like polypeptides with increased binding affinity for thrombosis
Human prourokinase-like polypeptides of which oligopeptides having a structure to form a covalent bond with blood clot (thrombus) through enzymatic action of human blood coagulation factor XIII are...
|
|
|
5317097 |
Mutations in the gene encoding the α chain on platelet glycoprotein IB
The subject invention provides purified polypeptides encoded by naturally-occurring wild-type platelet glycoprotein Ib alpha having a mutation which renders the polypeptide more reactive with von...
|
|
|
5308756 |
Protein S chromogenic assay
A chromogenic assay for determination of Protein S, using an indicator of Factor Xa as a measure of Protein S concentration. This technique utilizes the dependency of activated Protein C on Protein...
|
|
|
5302518 |
Process for the biocatalytic, correct chain folding of denatured recombinant fusion proteins
Denatured recombinant fusion proteins are correctly folded in the presence of a heat shock protein which acts according to the functional principle of the bacterial GroEL or of the equivalent...
|
|
|
5298420 |
Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface
Membrane anchoring peptides are attached to the C terminal end of the heavy chain of the various immunoglobulin isotypes (IgM, IgD, IgA, IgE, or IgG). The membrane anchoring peptides span the cell...
|
|
|
5298599 |
Expression and purification of recombinant soluble tissue factor
A method is disclosed to make any protein in a form that can be isolated rapidly from a solution using a specific monoclonal antibody designated "HPC-4". It has now been determined that it is...
|
|
|
5298603 |
GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use
Expression of a gene coding for human granulocyte macrophage colony-stimulating factor (CSF) in bacteria results in CSF proteins which are biologically active. Modification of the natural or of a...
|
|
|
5294699 |
Inhibition of coloration of human serum albumin
A method of inhibiting the coloration of human serum albumin expressed by using the gene manipulation technology which method comprises separating coloring contaminants from said human serum...
|
|
|
5292654 |
Mutant EPO receptor and uses therefor
A mutant erythropoietin receptor of mammalian origin which is hypersensitive to erythropoietin, DNA encoding the mutant erythropoietin receptor and uses therefor. An assay method for identifying...
|
|
|
5284827 |
Systemic treatment of metastatic cancer with platelet factor 4
The subject invention concerns a novel treatment for cancer. Specifically, the invention concerns the systemic administration of recombinant Platelet Factor Four (rPF4) to inhibit tumor growth in a...
|
|
|
5278144 |
Antithrombosis agents
Analogs of Factor Xa (Factor Xai) which are inactive as proteases in the prothrombinase reaction are useful in treatment of diseases characterized by thrombosis. These antithrombotic agents can be...
|
|
|
5272263 |
DNA sequences encoding vascular cell adhesion molecules (VCAMS)
DNA sequences encoding vascular cell adhesion molecules 1 and 1b ("VCAM1" and "VCAM1B"), recombinant DNA molecules comprising those sequences, and unicellular hosts transformed with those...
|
|
|
5270040 |
Vectors and compounds for expression of human protein C
The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that...
|
|
|
5270178 |
Vectors and compounds for expression of zymogen forms of human protein C
A method for the recombinant production of zymogen forms of human protein C is described. These zymogen forms differ from native zymogen protein C in their increased sensitivity to activation by...
|
|
|
5268275 |
Vitamin K-dependent carboxylase
Isolated DNA encoding a vitamin K dependent carboxylase is disclosed. The carboxylase is selected from the group consisting of: (a) isolated DNA which encodes bovine or human vitamin K dependent...
|
|
|
5260203 |
Single polypeptide chain binding molecules
The invention pertains to a single polypeptide chain binding molecule which has binding specificity and affinity substantially similar to the binding specificity and affinity of the light and heavy...
|
|
|
5260202 |
Fermentation method
The recoverable yield of recombinant human albumin in the fermentation of genetically engineered yeast that expresses the albumin and secretes it into the culture medium is increased by the...
|
|
|
5258289 |
Method for the selecting of genes encoding catalytic antibodies
The present invention describes methods of screening for or selecting a catalytic antibody effective to cleave a target peptide. In particular, in the selection method of the present invention a...
|
|
|
5258288 |
Vector containing DNA encoding mature human protein S
Disclosed are a transformed mammalian cell that produces biologically active Protein S, and a vector for effecting the transformation of the cell. produces biologically active human Protein S, and...
|
|
|
5256769 |
Mutual separation of proteins
A protein of interest or a Met-protein, e.g. the N-Met analog of the protein of the interest can be efficiently separated from a mixture thereof by subjecting the mixture to a separation procedure...
|
|
|
5256770 |
Oxidation resistant thrombomodulin analogs
Novel soluble oxidation resistant thrombomodulin analogs are produced for various therapeutic and other uses, such as in thrombotic and vascular disease therapies. These analogs exhibit the...
|
|
|
5250421 |
Method for producing factor VIII:C-type proteins
An improved method for producing Factor VIII:c-type proteins is disclosed which involves culturing mammalian cells which are capable of expressing the protein. In accordance with this invention the...
|
|
|
5245015 |
Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
The monoclonal antibodies (mAbs) of the invention bind to a neutralizing epitope on the gp120 glycoprotein of HIV-1. The binding seems to be conformation-dependent, in the sense that altering the...
|
|
|
5242807 |
Recombinant gene encoding human Charcot-Leyden crystal protein
A recombinant DNA molecule consisting of segments of DNA from different genomes which have been joined end-to-end outside of living cells, and the progeny of such a recombinant DNA molecule, which...
|
|
|
5242810 |
Bifunctional inhibitors of thrombin and platelet activation
The present invention relates to novel, bifunctional inhibitors of both platelet activation and thrombin. These bifunctional inhibitors are characterized by two domains -- a glycoprotein IIb/IIIa...
|
|
|
5225537 |
Methods for producing hybrid phospholipid-binding proteins
Methods are disclosed for producing hybrid phospholipid-binding proteins from eukaryotic cells. DNA constructs comprising a transcriptional promoter, at least one signal sequence and a hybrid...
|
|
|
5225539 |
Recombinant altered antibodies and methods of making altered antibodies
An altered antibody is produced by replacing the complementarity determining regions (CDRs) of a variable region of an immunoglobulin (Ig) with the CDRs from an Ig of different specificity, using...
|
|
|
5223256 |
Thrombolytically active non-glycosylated protein
A new thrombolytically active protein is not glycosylated and consists of the following amino acid sequence: ##STR1## or said amino acid sequence with an additional N-terminal methionine. DNA...
|
|
|
5223417 |
Method for transforming human B lymphocytes
Disclosed herein is a method for transforming human B-cells preferably by infecting them with Epstein-Barr virus followed by transforming the Epstein Barr virus infected cells with an activated...
|
|
|
5223422 |
t-PA mutant GK1L
The invention concerns a recombinant DNA which codes for a protein with the domains G, K1 and L of t-PA in which the sequences coding for the domains K2 and F of the wild-type t-PA gene or the...
|
|
|
5219740 |
Retroviral gene transfer into diploid fibroblasts for gene therapy
A process of mammalian gene therapy. Explanted fibroblasts are genetically modified by introducing a retroviral construct containing a nucleotide sequence encoding for a therapeutic substance. The...
|
|
|
5219996 |
Recombinant antibodies and methods for their production in which surface residues are altered to cysteine residues for attachment of effector or receptor molecules
The present invention provides an altered antibody molecule wherein a residue in a surface pocket on the molecule has been changed to a cysteine residue to introduce a thiol group in the surface...
|
|
|
5220006 |
Identification of a suppressor of atherogenic apolipoprotein
A region in the apolipoprotein B gene has been identified that suppresses the transcription of apolipoprotein B. Polypeptides that bind to the suppressor region have been isolated.
|
|
|
5218092 |
Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
A polypeptide or glycosylated polypeptide with at least one new carbohydrate chain produced by means of recombinant DNA technique, which has protease resistance and thermal stability and is...
|
|
|
5212091 |
Method of producing tissue factor pathway inhibitor
A method is disclosed for the production of tissue factor pathway inhibitor (TFPI) which comprises expression of a non-glycosylated form of TFPI in E. coli as host and obtaining a highly active...
|
|
|
5212074 |
Genetic material encoding new insulin-like growth factor binding protein IGFBP-6
A purified binding protein selected from the group consisting of insulin-like growth factor binding protein having an amino acid sequence which is at least 85% homologous to the amino acid sequence...
|